Application for White Spot Syndrome Virus (WSSV) Monitoring using Edge Machine Learning

The aquaculture industry, strongly reliant on shrimp exports, faces challenges due to viral infections like the White Spot Syndrome Virus (WSSV) that severely impact output yields. In this context, computer vision can play a significant role in identifying features not immediately evident to skilled or untrained eyes, potentially reducing the time required to report WSSV infections. In this study, the challenge of limited data for WSSV recognition was addressed. A mobile application dedicated to data collection and monitoring was developed to facilitate the creation of an image dataset to train a WSSV recognition model and improve country-wide disease surveillance. The study also includes a thorough analysis of WSSV recognition to address the challenge of imbalanced learning and on-device inference. The models explored, MobileNetV3-Small and EfficientNetV2-B0, gained an F1-Score of 0.72 and 0.99 respectively. The saliency heatmaps of both models were also observed to uncover the "black-box" nature of these models and to gain insight as to what features in the images are most important in making a prediction. These results highlight the effectiveness and limitations of using models designed for resource-constrained devices and balancing their performance in accurately recognizing WSSV, providing valuable information and direction in the use of computer vision in this domain.Comment: 6 pages, 7 figures, conferenc

The evidence for services to avoid or delay residential aged care admission: A systematic review

Background Interventions that enable people to remain in their own home as they age are of interest to stakeholders, yet detailed information on effective interventions is scarce. Our objective was to systematically search and synthesise evidence for the effectiveness of community-based, aged care interventions in delaying or avoiding admission to residential aged care. Method Nine databases were searched from January 2000 to February 2018 for English publications. Reference lists of relevant publications were searched. The databases yielded 55,221 citations and 50 citations were gleaned from other sources. Where there was sufficient homogeneity of study design, population, intervention and measures, meta-analyses were performed. Studies were grouped by the type of intervention: complex multifactorial interventions, minimal/single focus interventions, restorative programs, or by the target population (e.g. participants with dementia). Results Data from 31 randomised controlled trials (32 articles) that met our inclusion criteria were extracted and analysed. Compared to controls, complex multifactorial interventions in community aged care significantly improved older adults’ ability to remain living at home (risk difference − 0.02; 95% CI -0.03, − 0.00; p = 0.04). Commonalities in the 13 studies with complex interventions were the use of comprehensive assessment, regular reviews, case management, care planning, referrals to additional services, individualised interventions, frequent client contact if required, and liaison with General Practitioners. Complex interventions did not have a significantly different effect on mortality. Single focus interventions did not show a significant effect in reducing residential aged care admissions (risk difference 0, 95% CI -0.01, 0.01; p = 0.71), nor for mortality or quality of life. Subgroup analysis of complex interventions for people with dementia showed significant risk reduction for residential aged care admissions (RD -0.05; 95% CI -0.09, -0.01; p = 0.02). Compared to controls, only interventions targeting participants with dementia had a significant effect on improving quality of life (SMD 3.38, 95% CI 3.02, 3.74; p \u3c 0.000001). Conclusions Where the goal is to avoid residential aged care admission for people with or without dementia, there is evidence for multifactorial, individualised community programs. The evidence suggests these interventions do not result in greater mortality and hence are safe. Minimal, single focus interventions will not achieve the targeted outcomes. Trial registration PROSPERO Registration CRD42016050086

Evaluation of the Antimicrobial Activity of American Cockroach (Periplaneta americana) Ethanolic Tissue Extract against Selected Enteric Pathogens

Gastrointestinal (GI) tract infections caused by pathogenic microorganisms have a significant role in the global increase in mortality. This issue sparked an investigation into metabolites derived from numerous organisms that may have antimicrobial property against bacterial infections. The Kirby-Bauer Disc Diffusion method was used to test the extract of the American cockroach (Periplaneta americana) against enteric bacteria. The results indicate that the ethanolic extract of P. americana exhibited antimicrobial activity against the test pathogens, with the greatest inhibitory activity against Vibrio parahaemolyticus (p = 0.00013) and Candida albicans (p = 0.000911), when compared to the antibiotic controls Rifampicin, Trimethoprim, Ofloxacin, Penicillin, and antifungal drug Nystatin. However, there was no evidence of inhibitory activity against Enterococcus faecalis, Salmonella enteritidis, and Serratia marcescens. Thus, the current findings indicate that P. americana tissue extract may have antibacterial activity against medically important pathogens

Evaluation of the Antimicrobial Activity of American Cockroach (Periplaneta americana) Ethanolic Tissue Extract against Selected Enteric Pathogens

Gastrointestinal (GI) tract infections caused by pathogenic microorganisms have a significant role in the global increase in mortality. This issue sparked an investigation into metabolites derived from numerous organisms that may have antimicrobial property against bacterial infections. The Kirby-Bauer Disc Diffusion method was used to test the extract of the American cockroach (Periplaneta americana) against enteric bacteria. The results indicate that the ethanolic extract of P. americana exhibited antimicrobial activity against the test pathogens, with the greatest inhibitory activity against Vibrio parahaemolyticus (p = 0.00013) and Candida albicans (p = 0.000911), when compared to the antibiotic controls Rifampicin, Trimethoprim, Ofloxacin, Penicillin, and antifungal drug Nystatin. However, there was no evidence of inhibitory activity against Enterococcus faecalis, Salmonella enteritidis, and Serratia marcescens. Thus, the current findings indicate that P. americana tissue extract may have antibacterial activity against medically important pathogens

Reporting of Methodologic Information on Trial Registries for Quality Assessment: A Study of Trial Records Retrieved from the WHO Search Portal

Background: Although randomized clinical trials (RCTs) are considered the gold standard of evidence, their reporting is often suboptimal. Trial registries have the potential to contribute important methodologic information for critical appraisal of study results. Methods and Findings: The objective of the study was to evaluate the reporting of key methodologic study characteristics in trial registries. We identified a random sample (n = 265) of actively recruiting RCTs using the World Health Organization International Clinical Trials Registry Platform (ICTRP) search portal in 2008. We assessed the reporting of relevant domains from the Cochrane Collaboration’s ‘Risk of bias’ tool and other key methodological aspects. Our primary outcomes were the proportion of registry records with adequate reporting of random sequence generation, allocation concealment, blinding, and trial outcomes. Two reviewers independently assessed each record. Weighted overall proportions in the ICTRP search portal for adequate reporting of sequence generation, allocation concealment, blinding (including and excluding open label RCT) and primary outcomes were 5.7% (95% CI 3.0–8.4%), 1.4% (0–2.8%), 41% (35–47%), 8.4% (4.1–13%), and 66% (60–72%), respectively. The proportion of adequately reported RCTs was higher for registries that used specific methodological fields for describing methods of randomization and allocation concealment compared to registries that did not. Concerning other key methodological aspects, weighted overall proportions of RCTs with adequately reported items were as follows: eligibility criteria (81%), secondary outcomes (46%), harm (5%) follow-up duration (62%), description of the interventions (53%) and sample size calculation (1%). Conclusions: Trial registries currently contain limited methodologic information about registered RCTs. In order to permit adequate critical appraisal of trial results reported in journals and registries, trial registries should consider requesting details on key RCT methods to complement journal publications. Full protocols remain the most comprehensive source of methodologic information and should be made publicly available

Epidermal RAF prevents allergic skin disease

The RAS pathway is central to epidermal homeostasis, and its activation in tumors or in Rasopathies correlates with hyperproliferation. Downstream of RAS, RAF kinases are actionable targets regulating keratinocyte turnover; however, chemical RAF inhibitors paradoxically activate the pathway, promoting epidermal proliferation. We generated mice with compound epidermis restricted BRAF/RAF1 ablation. In these animals, transient barrier defects and production of chemokines and Th2-type cytokines by keratinocytes cause a disease akin to human atopic dermatitis, characterized by IgE responses and local and systemic inflammation. Mechanistically, BRAF and RAF1 operate independently to balance MAPK signaling: BRAF promotes ERK activation, while RAF1 dims stress kinase activation. In vivo, JNK inhibition prevents disease onset, while MEK/ERK inhibition in mice lacking epidermal RAF1 phenocopies it. These results support a primary role of keratinocytes in the pathogenesis of atopic dermatitis, and the animals lacking BRAF and RAF1 in the epidermis represent a useful model for this disease

Completeness and Changes in Registered Data and Reporting Bias of Randomized Controlled Trials in ICMJE Journals after Trial Registration Policy

We assessed the adequacy of randomized controlled trial (RCT) registration, changes to registration data and reporting completeness for articles in ICMJE journals during 2.5 years after registration requirement policy.For a set of 149 reports of 152 RCTs with ClinicalTrials.gov registration number, published from September 2005 to April 2008, we evaluated the completeness of 9 items from WHO 20-item Minimum Data Set relevant for assessing trial quality. We also assessed changes to the registration elements at the Archive site of ClinicalTrials.gov and compared published and registry data.RCTs were mostly registered before 13 September 2005 deadline (n = 101, 66.4%); 118 (77.6%) started recruitment before and 31 (20.4%) after registration. At the time of registration, 152 RCTs had a total of 224 missing registry fields, most commonly 'Key secondary outcomes' (44.1% RCTs) and 'Primary outcome' (38.8%). More RCTs with post-registration recruitment had missing Minimum Data Set items than RCTs with pre-registration recruitment: 57/118 (48.3%) vs. 24/31 (77.4%) (χ(2) (1) = 7.255, P = 0.007). Major changes in the data entries were found for 31 (25.2%) RCTs. The number of RCTs with differences between registered and published data ranged from 21 (13.8%) for Study type to 118 (77.6%) for Target sample size.ICMJE journals published RCTs with proper registration but the registration data were often not adequate, underwent substantial changes in the registry over time and differed in registered and published data. Editors need to establish quality control procedures in the journals so that they continue to contribute to the increased transparency of clinical trials

Compliance of clinical trial registries with the World Health Organization minimum data set : a survey

BACKGROUND: Since September 2005 the International Committee of Medical Journal Editors has required that trials be registered in accordance with the World Health Organization (WHO) minimum dataset, in order to be considered for publication. The objective is to evaluate registries' and individual trial records' compliance with the 2006 version of the WHO minimum data set. METHODS: A retrospective evaluation of 21 online clinical trial registries (international, national, specialty, pharmaceutical industry and local) from April 2005 to February 2007 and a cross-sectional evaluation of a stratified random sample of 610 trial records from the 21 registries. RESULTS: Among 11 registries that provided guidelines for registration, the median compliance with the WHO criteria were 14 out of 20 items (range 6 to 20). In the period April 2005-February 2007, six registries increased their compliance by six data items, on average. None of the local registry websites published guidelines on the trial data items required for registration. Slightly more than half (330/610; 54.1%, 95% CI 50.1% - 58.1%) of trial records completed the contact details criteria while 29.7% (181/610, 95% CI 26.1% - 33.5%) completed the key clinical and methodological data fields. CONCLUSION: While the launch of the WHO minimum data set seemed to positively influence registries with better standardisation of approaches, individual registry entries are largely incomplete. Initiatives to ensure quality assurance of registries and trial data should be encouraged. Peer reviewers and editors should scrutinise clinical trial registration records to ensure consistency with WHO's core content requirements when considering trial-related publications